Harvard Bioscience Inc
NASDAQ:HBIO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (1.1), the stock would be worth $20.73 (221% upside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.3 | $6.45 |
0%
|
| 3-Year Average | 1.1 | $20.73 |
+221%
|
| 5-Year Average | 1.3 | $24.82 |
+285%
|
| Industry Average | 5.1 | $97.82 |
+1 417%
|
| Country Average | 2.4 | $47.14 |
+631%
|
Forward P/S
Today’s price vs future revenue
| Today's Market Cap | Revenue | Forward P/S | ||
|---|---|---|---|---|
|
$24m
|
/ |
Jan 2026
$86.6m
|
= |
|
|
$24m
|
/ |
Dec 2026
$90.7m
|
= |
|
|
$24m
|
/ |
Dec 2027
$98.4m
|
= |
|
Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Harvard Bioscience Inc
NASDAQ:HBIO
|
28.8m USD | 0.3 | -0.5 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
958.5B USD | 335.6 | 3 973.8 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
174.7B USD | 3.9 | 25.5 | |
| US |
|
Danaher Corp
NYSE:DHR
|
126.7B USD | 5.1 | 34.3 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 18.1 | 46.1 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
329.9B CNY | 7.3 | 17.3 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
33.1B CHF | 5.1 | -120.5 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
32.5B USD | 4.6 | 25.2 | |
| US |
|
Waters Corp
NYSE:WAT
|
29.5B USD | 9.3 | 45.9 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
27B USD | 1.7 | 19.9 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
25.7B USD | 6.4 | 29.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.2 |
| Median | 2.4 |
| 70th Percentile | 4.1 |
| Max | 4 613 274.2 |
Other Multiples
Harvard Bioscience Inc
Glance View
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. The company is headquartered in Holliston, Massachusetts and currently employs 475 full-time employees. The company went IPO on 2013-10-21. The firm provides products that support research in six different classes of laboratory use, including molecular, cellular, tissue, organ, organisms or preclinical, and clinical. The firm organizes its product line activities into two product families, Cellular and Molecular Technologies (CMT) and Preclinical. The company primarily sells its products under several brand names, including Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS. The firm's customers include pharmaceutical and biotechnology companies, as well as contract research organizations, academic labs, and government researchers.
